About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More


ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Study identifier: NCT01012817
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)


  • Histologically confirmed ovarian epithelial or primary peritoneal cancer
  • Refractory to platinum-based therapy OR relapsed < 1 year after receiving a prior platinum-based regimen
  • Measurable disease, defined as ≥ 1 lesion whose longest diameter can be accurately measured as ≥ 2.0 cm with conventional techniques or as ≥ 1.0 cm with spiral CT scan
  • More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C and nitrosoureas) and recovered
  • No history of dose reductions for neutropenia or thrombocytopenia with prior chemotherapy
  • No more than 2 prior therapeutic regimens for ovarian epithelial cancer or primary peritoneal cancer

Type of study:

Phase I/II study


Veliparib and topotecan hydrochloride

Study sites:

Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259-5499
Contact: Clinical Trials Office - All Mayo Clinic Locations

Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Contact: Clinical Trials Office - All Mayo Clinic Locations

Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Contact: Clinical Trials Office - All Mayo Clinic Locations

Page updated 08/31/11

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us


This site has been made possible by a generous grant from Morphotek.

Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org